Published Manuscripts (2009)

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obesity and Metabolism 2009; 11(11): 1068-79.

Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ. Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 2009; 12(Suppl 3): S55-S61.

Smith-Palmer J, Kalsekar A, Boye K and Goodall G. The Impact of Obesity on Adverse Cardiovascular Outcomes in the General Population and in Patients with Type 2 Diabetes Clinical Medicine. Endocrinology and Diabetes 2009; 2: 43-69.

Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocrine Disorders 2009; 5: 9-19.

Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ. An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. Diabetic Medicine 2009; 26(8): 803-14.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P and Valentine WJ. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International Journal of Clinical Pharmacology and Therapeutics 2009; 47(8): 501-515.

Gschwend MG, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 2009; 12(2): 114-123.

Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Effectiveness and Resource Allocation 2009; 7(1): 9.

Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Medical Weekly 2009; 139(11-12): 173-84.